NASDAQ:STOK Stoke Therapeutics Q3 2024 Earnings Report $29.03 -0.31 (-1.06%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$29.00 -0.04 (-0.12%) As of 09/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Stoke Therapeutics EPS ResultsActual EPS-$0.47Consensus EPS -$0.52Beat/MissBeat by +$0.05One Year Ago EPSN/AStoke Therapeutics Revenue ResultsActual Revenue$4.89 millionExpected Revenue$3.46 millionBeat/MissBeat by +$1.43 millionYoY Revenue GrowthN/AStoke Therapeutics Announcement DetailsQuarterQ3 2024Date11/5/2024TimeBefore Market OpensConference Call DateTuesday, November 5, 2024Conference Call Time7:00AM ETUpcoming EarningsStoke Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Stoke Therapeutics Earnings HeadlinesStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of ...September 3, 2026 | markets.businessinsider.comStoke Therapeutics Inc 0GTSeptember 1, 2026 | morningstar.comMThree companies about to leapfrog Nvidia [And transform the entire industry]Three under-the-radar companies are already building the infrastructure behind a 200 billion government-backed tech push, according to analyst George Gilder. Gilder calls it the Trillion Dollar Triangle, technology he says makes today's AI infrastructure look outdated. All three companies are already moving, not just planned.September 12 at 1:00 AM | Eagle Publishing (Ad)Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congressSeptember 1, 2026 | msn.comStoke Therapeutics shares rise as JPMorgan starts coverage with Overweight ratingAugust 21, 2026 | finance.yahoo.comStoke Therapeutics (STOK) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | finance.yahoo.comSee More Stoke Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email. Email Address About Stoke TherapeuticsStoke Therapeutics (NASDAQ:STOK) is a biotechnology company focused on developing RNA-based medicines for severe genetic diseases. The company’s approach is designed to increase the production of functional proteins by selectively targeting RNA splicing, a process that helps determine how genetic information is translated into proteins. Stoke’s technology is based on its TANGO platform, which uses antisense oligonucleotides to promote the inclusion of productive genetic sequences in messenger RNA. Its lead investigational medicine, STK-001, is being developed for Dravet syndrome, a severe form of epilepsy commonly associated with mutations in the SCN1A gene. STK-001 is intended to increase production of functional Nav1.1 protein and is being evaluated in clinical studies. Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke serves the global rare-disease and genetic-medicine market through research and clinical development activities. The company’s leadership includes Edward M. Kaye, M.D., who serves as chief executive officer and has experience in the development of treatments for rare neurological disorders.View Stoke Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
